36 related articles for article (PubMed ID: 38532756)
1. Metastatic progression of breast cancer along with decreased mitochondrial cell death priming of breast cancer cells: a case report.
Aka Y; Ozdemir H; Torun N; Bolat FA; Kutuk O
Oxf Med Case Reports; 2024 Mar; 2024(3):omae014. PubMed ID: 38532756
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
[TBL] [Abstract][Full Text] [Related]
4. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
[TBL] [Abstract][Full Text] [Related]
5. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
6. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD; Bardia A; Chirn B; Reeves BA; LiCausi JA; Burr R; Wittner BS; Rai S; Patel H; Bihani T; Arlt H; Bidard FC; Kaklamani VG; Aftimos P; Cortés J; Scartoni S; Fiascarelli A; Binaschi M; Habboubi N; Iafrate AJ; Toner M; Haber DA; Maheswaran S
Breast Cancer Res Treat; 2023 Aug; 201(1):43-56. PubMed ID: 37318638
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.
Cheng X; Sun Y; Highkin M; Vemalapally N; Jin X; Zhou B; Prior JL; Tipton AR; Li S; Iliuk A; Achilefu S; Hagemann IS; Edwards JR; Bose R
Cancer Res; 2023 Sep; 83(17):2839-2857. PubMed ID: 37272756
[TBL] [Abstract][Full Text] [Related]
8. Cancer statistics, 2023.
Siegel RL; Miller KD; Wagle NS; Jemal A
CA Cancer J Clin; 2023 Jan; 73(1):17-48. PubMed ID: 36633525
[TBL] [Abstract][Full Text] [Related]
9. Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.
Sivakumar S; Jin DX; Tukachinsky H; Murugesan K; McGregor K; Danziger N; Pavlick D; Gjoerup O; Ross JS; Harmon R; Chung J; Decker B; Dennis L; Frampton GM; Molinero L; Oesterreich S; Venstrom JM; Oxnard GR; Hegde PS; Sokol ES
Nat Commun; 2022 Dec; 13(1):7495. PubMed ID: 36470901
[TBL] [Abstract][Full Text] [Related]
10. Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report.
Azzi G; Krinshpun S; Tin A; Maninder M; Malashevich AK; Malhotra M; Vega RR; Billings PR; Rodriguez A; Aleshin A
Case Rep Oncol; 2022; 15(2):473-479. PubMed ID: 35702676
[TBL] [Abstract][Full Text] [Related]
11. Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer.
Potter DS; Du R; Bhola P; Bueno R; Letai A
Cell Death Dis; 2021 Jul; 12(8):741. PubMed ID: 34315868
[TBL] [Abstract][Full Text] [Related]
12. High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors.
Bhola PD; Ahmed E; Guerriero JL; Sicinska E; Su E; Lavrova E; Ni J; Chipashvili O; Hagan T; Pioso MS; McQueeney K; Ng K; Aguirre AJ; Cleary JM; Cocozziello D; Sotayo A; Ryan J; Zhao JJ; Letai A
Sci Signal; 2020 Jun; 13(636):. PubMed ID: 32546544
[TBL] [Abstract][Full Text] [Related]
13. Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer.
Cheng FT; Lapke N; Wu CC; Lu YJ; Chen SJ; Yu PN; Liu YT; Tan KT
Case Rep Oncol Med; 2019; 2019():6545298. PubMed ID: 31583146
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
